Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogensInfex to present results from Phase IIa trial for first-in-class anti-virulence therapy RESP-X at ATS 2026...
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
